Condition: Pancreatic Ductal Adenocarcinoma (PDAC) · Sponsor: The University of Texas Health Science Center, Houston
The objectives of this study are to determine the feasibility, tolerability, and treatment effect of endoscopic ultrasound (EUS) radiofrequency ablation (RFA) plus standard-of-care neoadjuvant chemotherapy (NAC) in the treatment of pancreatic ductal adenocarcinoma (PDAC). Endoscopic ultrasound (EUS) radiofrequency ablation (RFA) and neoadjuvant chemotherapy (NAC) will be performed before tumor resection surgery, with the goal of shrinking a tumor or stopping the spread of cancer so that surgery might be less invasive and more effective.
This description comes directly from the study's public registry record.
Sofia C Colon, BS · 713-500-6658 · Sofia.C.Colon@uth.tmc.edu
Nirav Thosani, MD · 713-486-1350 · pancreasresearch@uth.tmc.edu
Always discuss trial participation with your own doctor first.
| Memorial Hermann Hospital | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04990609